Heralding a new paradigm in 3D tumor modeling

Area of Science:

• Cancer biology
• Tumor engineering
• 3D cell culture models

Background:

• Traditional cancer research relied on 2D cell cultures, which fail to represent tumor complexity.
• Tumors are complex tissues with extracellular matrix, stromal, immune, and endothelial cells, not just proliferating cancer cells.
• Cancer cell lines used in traditional models poorly reflect intrinsic tumor heterogeneity, contributing to drug development failures.

Purpose of the Study:

• To review advances in recapitulating tumor complexity using 3D in vitro models.
• To discuss the importance of incorporating tumor heterogeneity into 3D tumor models.
• To provide a roadmap for future 3D tumor engineering.

Main Methods:

• Development of engineered matrices and co-cultures to replicate tumor-stroma interactions in vitro.
• Shift from cancer cell lines to patient-derived xenografts and organoids for more representative tumor modeling.
• Focus on incorporating tumor variants and tumor-stroma interactions in 3D models.

Main Results:

• Significant progress has been made in recapitulating the tumor microenvironment in 3D.
• Patient-derived primary tumor cells (xenografts, organoids) are emerging as superior alternatives to cell lines.
• Acknowledging tumor heterogeneity alongside complexity is key for future 3D model development.

Conclusions:

• 3D tumor models are essential for accurately studying cancer biology and improving drug development.
• Incorporating tumor heterogeneity into 3D models is critical for overcoming therapeutic resistance.
• Future research in tumor engineering must integrate both tumor complexity and heterogeneity for effective cancer treatment strategies.